期刊
JOURNAL OF CLINICAL GASTROENTEROLOGY
卷 41, 期 9, 页码 799-809出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCG.0b013e318033d71d
关键词
ulcerative colitis; Crohn's disease; 5-ASA; AZA/6-MP; infliximab
Most physicians believe that the drugs they prescribe will work in their patients and thus have made little preparation for alternative strategies in the event of failure. In the treatment of inflammatory bowel disease (IBD), achieving a remission rate of 20% to 30% or a response rate of 50% to 60% is highly acceptable. This review focuses primarily on placebo-controlled trials that evaluated usual treatments for IBD in terms of induction and maintenance of remission, and identifies the gaps (ie, the percentage of patients lacking any benefit) in currently available treatments for IBD. Approximately, 40% to 60% of patients will not benefit from the available treatments, indicating a considerable unmet need for new, more effective therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据